Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Immunotherapy Drugs Market by Therapy Area (Cancer, Autoimmune Inflammatory Diseases, Infectious Diseases, Others) and by Type (Monoclonal Antibodies, Adult Vaccines, Checkpoint Inhibitors, Interferons Alpha Beta, Interleukins, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

A03238

Pages: NA

Charts: NA

Tables: NA

Immunotherapy drugs are used to enhance or suppress the immune system of the body. They are mostly used in the treatment of cancer and act by stimulating the immune system of the body and generate an immune response aiding the production of antibodies. Antibodies produced against antigen kill the cancerous or tumor cells. The global immunotherapy drugs market is expected to grow significant growth during the forecast period due to increase in incidence of cancer.

The global immunotherapy market is driven by increasing adoption of targeted therapies, increase in life span of patients, and high prevalence of lifestyle diseases. Furthermore, rapid approval of drugs and reduction in recurrence of diseases propel the market growth. However, high cost of immunotherapy treatment and higher attrition rate in the product development cycle impede the market growth. Conversely, immunotherapy as an alternative to chemotherapy and use of immunotherapy as the first line of drug for the treatment of cancer provide growth opportunities in the market players in the near future.

The global immunotherapy drugs market is segmented based on therapy area, type of drugs, and region. Based on therapy area, it is divided into cancer, autoimmune & inflammatory diseases, infectious diseases, and others. Cancer is further divided into solid tumor and malignant tumor. Based on type of drugs, it is classified into monoclonal antibodies, adult vaccines, checkpoint inhibitors, interferons alpha & beta, interleukins, and others.

The adult vaccines segment is subdivided into preventive vaccines and therapeutic vaccines. On the basis of region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA further country level analysis of regions is provided to determine the market size and forecast for each segment and sub-segment of the market across the globe.

The major companies profiled in this report includes F. Hoffmann-La Roche AG, GlaxoSmithKline plc., AbbVie, Inc., Amgen, Inc., Merck & Co., Inc., Alligator Bioscience, UbiVac, Bristol-Myers Squibb, Novartis International AG, and AstraZeneca plc.

Key Benefits

  • The study provides an in-depth analysis of the market along with current trends and future estimations to elucidate the imminent investment pockets.
  • It offers a quantitative analysis of the industry to enable the stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis by product elucidates the various types of nanomedicines used for the treatment of cancer.
  • Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
  • Key players are profiled and their strategies have been analyzed thoroughly to understand the competitive outlook of the global market.

 Key Market Segments

  • By Therapy Area
    • Cancer
      • Solid Tumor
      • Malignant
    • Autoimmune & Inflammatory Diseases
    • Infectious Diseases
    • Others
  • By Type
    • Monoclonal Antibodies
    • Adult Vaccines
      • Preventive Vaccines
      • Therapeutic Vaccines
    • Checkpoint Inhibitors
    • Interferons Alpha & Beta
    • Interleukins
    • Others
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • Bristol-Myers Squibb
  • Alligator Bioscience
  • GlaxoSmithKline plc.
  • F. Hoffmann-La Roche AG
  • Merck & Co., Inc.
  • UbiVac
  • Amgen, Inc.
  • AbbVie, Inc.
  • Novartis International AG
  • AstraZeneca plc

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Therapy Area

    • 4.2. Cancer

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

      • 4.2.4. Solid Tumor

        • 4.2.4.1. Market Size and Forecast

      • 4.2.4. Malignant

        • 4.2.4.1. Market Size and Forecast

    • 4.3. Autoimmune And Inflammatory Diseases

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Infectious Diseases

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Others

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

  • CHAPTER 5: IMMUNOTHERAPY DRUGS MARKET, BY TYPE

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Type

    • 5.2. Monoclonal Antibodies

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Adult Vaccines

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

      • 5.3.4. Preventive Vaccines

        • 5.3.4.1. Market Size and Forecast

      • 5.3.4. Therapeutic Vaccines

        • 5.3.4.1. Market Size and Forecast

    • 5.4. Checkpoint Inhibitors

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Interferons Alpha And Beta

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

    • 5.6. Interleukins

      • 5.6.1. Key Market Trends, Growth Factors and Opportunities

      • 5.6.2. Market Size and Forecast, By Region

      • 5.6.3. Market Share Analysis, By Country

    • 5.7. Others

      • 5.7.1. Key Market Trends, Growth Factors and Opportunities

      • 5.7.2. Market Size and Forecast, By Region

      • 5.7.3. Market Share Analysis, By Country

  • CHAPTER 6: IMMUNOTHERAPY DRUGS MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Therapy Area

      • 6.2.3. Market Size and Forecast, By Type

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Immunotherapy Drugs Market

        • 6.2.5.1. Market Size and Forecast, By Therapy Area
        • 6.2.5.2. Market Size and Forecast, By Type

      • 6.2.6. Canada Immunotherapy Drugs Market

        • 6.2.6.1. Market Size and Forecast, By Therapy Area
        • 6.2.6.2. Market Size and Forecast, By Type

      • 6.2.7. Mexico Immunotherapy Drugs Market

        • 6.2.7.1. Market Size and Forecast, By Therapy Area
        • 6.2.7.2. Market Size and Forecast, By Type

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Therapy Area

      • 6.3.3. Market Size and Forecast, By Type

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Immunotherapy Drugs Market

        • 6.3.5.1. Market Size and Forecast, By Therapy Area
        • 6.3.5.2. Market Size and Forecast, By Type

      • 6.3.6. Germany Immunotherapy Drugs Market

        • 6.3.6.1. Market Size and Forecast, By Therapy Area
        • 6.3.6.2. Market Size and Forecast, By Type

      • 6.3.7. Italy Immunotherapy Drugs Market

        • 6.3.7.1. Market Size and Forecast, By Therapy Area
        • 6.3.7.2. Market Size and Forecast, By Type

      • 6.3.8. Spain Immunotherapy Drugs Market

        • 6.3.8.1. Market Size and Forecast, By Therapy Area
        • 6.3.8.2. Market Size and Forecast, By Type

      • 6.3.9. UK Immunotherapy Drugs Market

        • 6.3.9.1. Market Size and Forecast, By Therapy Area
        • 6.3.9.2. Market Size and Forecast, By Type

      • 6.3.10. Russia Immunotherapy Drugs Market

        • 6.3.10.1. Market Size and Forecast, By Therapy Area
        • 6.3.10.2. Market Size and Forecast, By Type

      • 6.3.11. Rest Of Europe Immunotherapy Drugs Market

        • 6.3.11.1. Market Size and Forecast, By Therapy Area
        • 6.3.11.2. Market Size and Forecast, By Type

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Therapy Area

      • 6.4.3. Market Size and Forecast, By Type

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Immunotherapy Drugs Market

        • 6.4.5.1. Market Size and Forecast, By Therapy Area
        • 6.4.5.2. Market Size and Forecast, By Type

      • 6.4.6. Japan Immunotherapy Drugs Market

        • 6.4.6.1. Market Size and Forecast, By Therapy Area
        • 6.4.6.2. Market Size and Forecast, By Type

      • 6.4.7. India Immunotherapy Drugs Market

        • 6.4.7.1. Market Size and Forecast, By Therapy Area
        • 6.4.7.2. Market Size and Forecast, By Type

      • 6.4.8. South Korea Immunotherapy Drugs Market

        • 6.4.8.1. Market Size and Forecast, By Therapy Area
        • 6.4.8.2. Market Size and Forecast, By Type

      • 6.4.9. Australia Immunotherapy Drugs Market

        • 6.4.9.1. Market Size and Forecast, By Therapy Area
        • 6.4.9.2. Market Size and Forecast, By Type

      • 6.4.10. Thailand Immunotherapy Drugs Market

        • 6.4.10.1. Market Size and Forecast, By Therapy Area
        • 6.4.10.2. Market Size and Forecast, By Type

      • 6.4.11. Malaysia Immunotherapy Drugs Market

        • 6.4.11.1. Market Size and Forecast, By Therapy Area
        • 6.4.11.2. Market Size and Forecast, By Type

      • 6.4.12. Indonesia Immunotherapy Drugs Market

        • 6.4.12.1. Market Size and Forecast, By Therapy Area
        • 6.4.12.2. Market Size and Forecast, By Type

      • 6.4.13. Rest of Asia Pacific Immunotherapy Drugs Market

        • 6.4.13.1. Market Size and Forecast, By Therapy Area
        • 6.4.13.2. Market Size and Forecast, By Type

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Therapy Area

      • 6.5.3. Market Size and Forecast, By Type

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Immunotherapy Drugs Market

        • 6.5.5.1. Market Size and Forecast, By Therapy Area
        • 6.5.5.2. Market Size and Forecast, By Type

      • 6.5.6. South Africa Immunotherapy Drugs Market

        • 6.5.6.1. Market Size and Forecast, By Therapy Area
        • 6.5.6.2. Market Size and Forecast, By Type

      • 6.5.7. Saudi Arabia Immunotherapy Drugs Market

        • 6.5.7.1. Market Size and Forecast, By Therapy Area
        • 6.5.7.2. Market Size and Forecast, By Type

      • 6.5.8. UAE Immunotherapy Drugs Market

        • 6.5.8.1. Market Size and Forecast, By Therapy Area
        • 6.5.8.2. Market Size and Forecast, By Type

      • 6.5.9. Argentina Immunotherapy Drugs Market

        • 6.5.9.1. Market Size and Forecast, By Therapy Area
        • 6.5.9.2. Market Size and Forecast, By Type

      • 6.5.10. Rest of LAMEA Immunotherapy Drugs Market

        • 6.5.10.1. Market Size and Forecast, By Therapy Area
        • 6.5.10.2. Market Size and Forecast, By Type

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning, 2024

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. F. Hoffmann-La Roche AG

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. GlaxoSmithKline Plc.

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. AbbVie, Inc.

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Amgen, Inc.

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Merck And Co., Inc.

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Alligator Bioscience

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. UbiVac

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. Bristol-Myers Squibb

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. Novartis International AG

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. AstraZeneca Plc

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL IMMUNOTHERAPY DRUGS MARKET FOR AUTOIMMUNE AND INFLAMMATORY DISEASES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL IMMUNOTHERAPY DRUGS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL IMMUNOTHERAPY DRUGS MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL IMMUNOTHERAPY DRUGS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL IMMUNOTHERAPY DRUGS MARKET FOR ADULT VACCINES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL IMMUNOTHERAPY DRUGS MARKET FOR CHECKPOINT INHIBITORS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL IMMUNOTHERAPY DRUGS MARKET FOR INTERFERONS ALPHA AND BETA, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL IMMUNOTHERAPY DRUGS MARKET FOR INTERLEUKINS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL IMMUNOTHERAPY DRUGS MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 14. NORTH AMERICA IMMUNOTHERAPY DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 15. NORTH AMERICA IMMUNOTHERAPY DRUGS, BY THERAPY AREA, 2025-2033 ($MILLION)
  • TABLE 16. NORTH AMERICA IMMUNOTHERAPY DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 17. U.S. IMMUNOTHERAPY DRUGS, BY THERAPY AREA, 2025-2033 ($MILLION)
  • TABLE 18. U.S. IMMUNOTHERAPY DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 19. CANADA IMMUNOTHERAPY DRUGS, BY THERAPY AREA, 2025-2033 ($MILLION)
  • TABLE 20. CANADA IMMUNOTHERAPY DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 21. MEXICO IMMUNOTHERAPY DRUGS, BY THERAPY AREA, 2025-2033 ($MILLION)
  • TABLE 22. MEXICO IMMUNOTHERAPY DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 23. EUROPE IMMUNOTHERAPY DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 24. EUROPE IMMUNOTHERAPY DRUGS, BY THERAPY AREA, 2025-2033 ($MILLION)
  • TABLE 25. EUROPE IMMUNOTHERAPY DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 26. FRANCE IMMUNOTHERAPY DRUGS, BY THERAPY AREA, 2025-2033 ($MILLION)
  • TABLE 27. FRANCE IMMUNOTHERAPY DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 28. GERMANY IMMUNOTHERAPY DRUGS, BY THERAPY AREA, 2025-2033 ($MILLION)
  • TABLE 29. GERMANY IMMUNOTHERAPY DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 30. ITALY IMMUNOTHERAPY DRUGS, BY THERAPY AREA, 2025-2033 ($MILLION)
  • TABLE 31. ITALY IMMUNOTHERAPY DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 32. SPAIN IMMUNOTHERAPY DRUGS, BY THERAPY AREA, 2025-2033 ($MILLION)
  • TABLE 33. SPAIN IMMUNOTHERAPY DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 34. UK IMMUNOTHERAPY DRUGS, BY THERAPY AREA, 2025-2033 ($MILLION)
  • TABLE 35. UK IMMUNOTHERAPY DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 36. RUSSIA IMMUNOTHERAPY DRUGS, BY THERAPY AREA, 2025-2033 ($MILLION)
  • TABLE 37. RUSSIA IMMUNOTHERAPY DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 38. REST OF EUROPE IMMUNOTHERAPY DRUGS, BY THERAPY AREA, 2025-2033 ($MILLION)
  • TABLE 39. REST OF EUROPE IMMUNOTHERAPY DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 40. ASIA-PACIFIC IMMUNOTHERAPY DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 41. ASIA-PACIFIC IMMUNOTHERAPY DRUGS, BY THERAPY AREA, 2025-2033 ($MILLION)
  • TABLE 42. ASIA-PACIFIC IMMUNOTHERAPY DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 43. CHINA IMMUNOTHERAPY DRUGS, BY THERAPY AREA, 2025-2033 ($MILLION)
  • TABLE 44. CHINA IMMUNOTHERAPY DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 45. JAPAN IMMUNOTHERAPY DRUGS, BY THERAPY AREA, 2025-2033 ($MILLION)
  • TABLE 46. JAPAN IMMUNOTHERAPY DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 47. INDIA IMMUNOTHERAPY DRUGS, BY THERAPY AREA, 2025-2033 ($MILLION)
  • TABLE 48. INDIA IMMUNOTHERAPY DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 49. SOUTH KOREA IMMUNOTHERAPY DRUGS, BY THERAPY AREA, 2025-2033 ($MILLION)
  • TABLE 50. SOUTH KOREA IMMUNOTHERAPY DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 51. AUSTRALIA IMMUNOTHERAPY DRUGS, BY THERAPY AREA, 2025-2033 ($MILLION)
  • TABLE 52. AUSTRALIA IMMUNOTHERAPY DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 53. THAILAND IMMUNOTHERAPY DRUGS, BY THERAPY AREA, 2025-2033 ($MILLION)
  • TABLE 54. THAILAND IMMUNOTHERAPY DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 55. MALAYSIA IMMUNOTHERAPY DRUGS, BY THERAPY AREA, 2025-2033 ($MILLION)
  • TABLE 56. MALAYSIA IMMUNOTHERAPY DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 57. INDONESIA IMMUNOTHERAPY DRUGS, BY THERAPY AREA, 2025-2033 ($MILLION)
  • TABLE 58. INDONESIA IMMUNOTHERAPY DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 59. REST OF ASIA PACIFIC IMMUNOTHERAPY DRUGS, BY THERAPY AREA, 2025-2033 ($MILLION)
  • TABLE 60. REST OF ASIA PACIFIC IMMUNOTHERAPY DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 61. LAMEA IMMUNOTHERAPY DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 62. LAMEA IMMUNOTHERAPY DRUGS, BY THERAPY AREA, 2025-2033 ($MILLION)
  • TABLE 63. LAMEA IMMUNOTHERAPY DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 64. BRAZIL IMMUNOTHERAPY DRUGS, BY THERAPY AREA, 2025-2033 ($MILLION)
  • TABLE 65. BRAZIL IMMUNOTHERAPY DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 66. SOUTH AFRICA IMMUNOTHERAPY DRUGS, BY THERAPY AREA, 2025-2033 ($MILLION)
  • TABLE 67. SOUTH AFRICA IMMUNOTHERAPY DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 68. SAUDI ARABIA IMMUNOTHERAPY DRUGS, BY THERAPY AREA, 2025-2033 ($MILLION)
  • TABLE 69. SAUDI ARABIA IMMUNOTHERAPY DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 70. UAE IMMUNOTHERAPY DRUGS, BY THERAPY AREA, 2025-2033 ($MILLION)
  • TABLE 71. UAE IMMUNOTHERAPY DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 72. ARGENTINA IMMUNOTHERAPY DRUGS, BY THERAPY AREA, 2025-2033 ($MILLION)
  • TABLE 73. ARGENTINA IMMUNOTHERAPY DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 74. REST OF LAMEA IMMUNOTHERAPY DRUGS, BY THERAPY AREA, 2025-2033 ($MILLION)
  • TABLE 75. REST OF LAMEA IMMUNOTHERAPY DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 76. F. HOFFMANN-LA ROCHE AG: KEY EXECUTIVES
  • TABLE 77. F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT
  • TABLE 78. F. HOFFMANN-LA ROCHE AG: OPERATING SEGMENTS
  • TABLE 79. F. HOFFMANN-LA ROCHE AG: PRODUCT PORTFOLIO
  • TABLE 80. F. HOFFMANN-LA ROCHE AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 81. GLAXOSMITHKLINE PLC.: KEY EXECUTIVES
  • TABLE 82. GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT
  • TABLE 83. GLAXOSMITHKLINE PLC.: OPERATING SEGMENTS
  • TABLE 84. GLAXOSMITHKLINE PLC.: PRODUCT PORTFOLIO
  • TABLE 85. GLAXOSMITHKLINE PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 86. ABBVIE, INC.: KEY EXECUTIVES
  • TABLE 87. ABBVIE, INC.: COMPANY SNAPSHOT
  • TABLE 88. ABBVIE, INC.: OPERATING SEGMENTS
  • TABLE 89. ABBVIE, INC.: PRODUCT PORTFOLIO
  • TABLE 90. ABBVIE, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 91. AMGEN, INC.: KEY EXECUTIVES
  • TABLE 92. AMGEN, INC.: COMPANY SNAPSHOT
  • TABLE 93. AMGEN, INC.: OPERATING SEGMENTS
  • TABLE 94. AMGEN, INC.: PRODUCT PORTFOLIO
  • TABLE 95. AMGEN, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 96. MERCK AND CO., INC.: KEY EXECUTIVES
  • TABLE 97. MERCK AND CO., INC.: COMPANY SNAPSHOT
  • TABLE 98. MERCK AND CO., INC.: OPERATING SEGMENTS
  • TABLE 99. MERCK AND CO., INC.: PRODUCT PORTFOLIO
  • TABLE 100. MERCK AND CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 101. ALLIGATOR BIOSCIENCE: KEY EXECUTIVES
  • TABLE 102. ALLIGATOR BIOSCIENCE: COMPANY SNAPSHOT
  • TABLE 103. ALLIGATOR BIOSCIENCE: OPERATING SEGMENTS
  • TABLE 104. ALLIGATOR BIOSCIENCE: PRODUCT PORTFOLIO
  • TABLE 105. ALLIGATOR BIOSCIENCE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 106. UBIVAC: KEY EXECUTIVES
  • TABLE 107. UBIVAC: COMPANY SNAPSHOT
  • TABLE 108. UBIVAC: OPERATING SEGMENTS
  • TABLE 109. UBIVAC: PRODUCT PORTFOLIO
  • TABLE 110. UBIVAC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 111. BRISTOL-MYERS SQUIBB: KEY EXECUTIVES
  • TABLE 112. BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
  • TABLE 113. BRISTOL-MYERS SQUIBB: OPERATING SEGMENTS
  • TABLE 114. BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO
  • TABLE 115. BRISTOL-MYERS SQUIBB: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 116. NOVARTIS INTERNATIONAL AG: KEY EXECUTIVES
  • TABLE 117. NOVARTIS INTERNATIONAL AG: COMPANY SNAPSHOT
  • TABLE 118. NOVARTIS INTERNATIONAL AG: OPERATING SEGMENTS
  • TABLE 119. NOVARTIS INTERNATIONAL AG: PRODUCT PORTFOLIO
  • TABLE 120. NOVARTIS INTERNATIONAL AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 121. ASTRAZENECA PLC: KEY EXECUTIVES
  • TABLE 122. ASTRAZENECA PLC: COMPANY SNAPSHOT
  • TABLE 123. ASTRAZENECA PLC: OPERATING SEGMENTS
  • TABLE 124. ASTRAZENECA PLC: PRODUCT PORTFOLIO
  • TABLE 125. ASTRAZENECA PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL IMMUNOTHERAPY DRUGS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL IMMUNOTHERAPY DRUGS MARKET
  • FIGURE 3. SEGMENTATION IMMUNOTHERAPY DRUGS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN IMMUNOTHERAPY DRUGS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALIMMUNOTHERAPY DRUGS MARKET
  • FIGURE 11. IMMUNOTHERAPY DRUGS MARKET SEGMENTATION, BY BY THERAPY AREA
  • FIGURE 12. IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. IMMUNOTHERAPY DRUGS MARKET FOR AUTOIMMUNE AND INFLAMMATORY DISEASES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. IMMUNOTHERAPY DRUGS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. IMMUNOTHERAPY DRUGS MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. IMMUNOTHERAPY DRUGS MARKET SEGMENTATION, BY BY TYPE
  • FIGURE 17. IMMUNOTHERAPY DRUGS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. IMMUNOTHERAPY DRUGS MARKET FOR ADULT VACCINES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. IMMUNOTHERAPY DRUGS MARKET FOR CHECKPOINT INHIBITORS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. IMMUNOTHERAPY DRUGS MARKET FOR INTERFERONS ALPHA AND BETA, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. IMMUNOTHERAPY DRUGS MARKET FOR INTERLEUKINS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 22. IMMUNOTHERAPY DRUGS MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 23. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 24. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 25. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 26. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 27. COMPETITIVE DASHBOARD
  • FIGURE 28. COMPETITIVE HEATMAP: IMMUNOTHERAPY DRUGS MARKET
  • FIGURE 29. TOP PLAYER POSITIONING, 2024
  • FIGURE 30. F. HOFFMANN-LA ROCHE AG: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 31. F. HOFFMANN-LA ROCHE AG: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 32. F. HOFFMANN-LA ROCHE AG: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 33. GLAXOSMITHKLINE PLC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 34. GLAXOSMITHKLINE PLC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 35. GLAXOSMITHKLINE PLC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 36. ABBVIE, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 37. ABBVIE, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 38. ABBVIE, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 39. AMGEN, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 40. AMGEN, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 41. AMGEN, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 42. MERCK AND CO., INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 43. MERCK AND CO., INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 44. MERCK AND CO., INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 45. ALLIGATOR BIOSCIENCE: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 46. ALLIGATOR BIOSCIENCE: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 47. ALLIGATOR BIOSCIENCE: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 48. UBIVAC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 49. UBIVAC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 50. UBIVAC: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 51. BRISTOL-MYERS SQUIBB: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 52. BRISTOL-MYERS SQUIBB: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 53. BRISTOL-MYERS SQUIBB: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 54. NOVARTIS INTERNATIONAL AG: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 55. NOVARTIS INTERNATIONAL AG: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 56. NOVARTIS INTERNATIONAL AG: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 57. ASTRAZENECA PLC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 58. ASTRAZENECA PLC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 59. ASTRAZENECA PLC: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Immunotherapy Drugs Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved